Current challenges and emerging solutions in dentistry for treating medication-related osteonecrosis of the jaw (MRONJ): the state of the art in the era of personalized medicine.
Cancer patients receiving high-dose intravenous antiresorptive drugs develop medication-related osteonecrosis of the jaw more frequently than those treated for osteoporosis. Clinical staging systems and various prevention, management, and adjunct therapies guide treatment selection, though personalised approaches remain challenging.
A plain-English summary of the study's own findings — we don't add our own claims or interpretation. Read the full paper for the complete methods and results, and apply your own clinical judgement.
Read the full study at the sourceRelated CPD from Vital Pulp
Once and for All: Does Flossing Prevent Caries?
What the evidence actually says — an honest, cited look at flossing, caries and gum health
The Recall — the month's most significant new dental research, summarised. Free.
Browse The Recall